Core Viewpoint - The company has announced a proposal for full circulation of H-shares, converting 357,245,794 unlisted shares held by six shareholders into H-shares, which represents approximately 68.9733% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the implementation of the H-share full circulation proposal on November 14, 2025 [1] - The conversion of unlisted shares into H-shares is subject to obtaining all necessary approvals, including filing with the China Securities Regulatory Commission [1] - The company plans to apply for the listing and trading of these H-shares on the main board of the Stock Exchange of Hong Kong [1]

Core Viewpoint - The company, Xuan Zhu Biological-B (02575.HK), announced the implementation of a full circulation of H-shares, converting approximately 357 million unlisted shares held by six shareholders into H-shares, which represents about 68.9733% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation [1] - The conversion involves approximately 357 million shares [1] - The converted shares account for about 68.9733% of the total issued shares [1]

軒竹生物科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 於 本 公 告 日 期，本 公 司 尚 未 向 中 國 證 監 會 申 請H股 全 流 通。本 公 司 轉 換 及 上 市 實 施 計 劃 的 詳 情 尚 未 落 實，將 予 轉 換 的 未 上 市 股 份 最 終 數 目 以 及 轉 換 及 上 市 的 完 成 須 待 中 國 證 監 會、聯 交 所 及 其 他 相 關 國 內 外 監 管 機 構 規 定 的 相 關 程 序 履 行 後 方 可 作 實。本 公 司 將 根 據 上 市 規 則 及╱或 內 幕 消 息 條 文 於 適 當 時 候 就H 股 全 流 通 以 及 轉 換 及 上 市 的 進 展 作 出 進 一 步 公 告。 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 軒竹生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02575 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 2 ...

Group 1 - XuanZhu Bio-B (02575) saw a significant increase in stock price, rising over 9% to reach a new high of 71.6 HKD, with a current price of 69.7 HKD and a trading volume of 38.59 million HKD [1] - The company announced that its product NG-350A, licensed from clinical-stage oncology company Akamis, received Fast Track designation from the FDA for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] - XuanZhu Bio holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2 - From October 30 to November 3, the National Healthcare Security Administration (NHSA) is conducting negotiations for the 2025 National Basic Medical Insurance Drug List, which includes price negotiations for innovative drugs [1] - XuanZhu Bio's drug Pyrocil has successfully passed the preliminary review for inclusion in the national medical insurance list, making its final inclusion critical for the company [1]

Group 1 - XuanZhu Bio-B (02575) saw a significant increase in stock price, rising over 9% to reach a new high of 71.6 HKD, with a current price of 69.7 HKD and a trading volume of 38.59 million HKD [1] - The company announced that its product NG-350A, licensed from clinical-stage oncology company Akamis, received Fast Track designation from the FDA for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] - XuanZhu Bio holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2 - From October 30 to November 3, the National Healthcare Security Administration (NHSA) is conducting negotiations for the 2025 National Basic Medical Insurance Drug List, which includes price negotiations for innovative drugs [1] - XuanZhu Bio's drug Pyrocil has successfully passed the preliminary review for inclusion in the national medical insurance list, making its final inclusion critical for the company [1]

Core Viewpoint - XuanZhu Bio-B (02575) experienced a significant stock price increase, reaching a new high of 71.6 HKD, following the announcement of FDA's Fast Track designation for its product NG-350A, aimed at treating locally advanced rectal cancer [1][1][1] Company Developments - XuanZhu Bio-B's stock rose over 9% at the close, with a current trading price of 69.7 HKD and a trading volume of 38.59 million HKD [1][1][1] - The company has exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1][1][1] Regulatory Updates - The National Healthcare Security Administration (NHSA) is conducting negotiations for the 2025 National Basic Medical Insurance Drug List, which includes price negotiations for innovative drugs [1][1][1] - XuanZhu Bio-B's product, Pyrocil, has successfully passed the preliminary review for inclusion in the national medical insurance list, which is crucial for its market access [1][1][1]

Core Viewpoint - The company XuanZhu Bio-B (02575) has received Fast Track designation from the FDA for its product NG-350A, which is intended for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] Group 1: Product Development - NG-350A is licensed from the clinical-stage oncology company Akamis Bio Ltd. [1] - The company holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2: Regulatory Significance - The Fast Track designation is a method to expedite the development and review of potential drugs [1] - Drugs granted Fast Track designation are aimed at treating serious conditions and addressing unmet medical needs, potentially being the first therapy for a specific disease or offering significant clinical advantages over existing therapies [1]

Core Viewpoint - The company XuanZhu Bio-B (02575) has received Fast Track designation from the FDA for its product NG-350A, which is intended for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] Group 1: Product Development - NG-350A is licensed from the clinical-stage oncology company Akamis Bio Ltd. [1] - The company holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2: Regulatory Significance - The Fast Track designation is a method to expedite the development and review of potential drugs [1] - Drugs granted Fast Track designation are aimed at treating serious conditions and addressing unmet medical needs, potentially being the first therapy for a specific disease or offering significant clinical advantages over existing therapies [1]

Core Viewpoint - XuanZhu Bio-B (02575.HK) has received Fast Track designation from the FDA for its product NG-350A, aimed at treating locally advanced rectal cancer with proficient mismatch repair (pMMR) [1] Group 1 - The product NG-350A is licensed from the clinical-stage oncology company Akamis [1] - The company holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1]